THROMBATE III Rx
Generic Name and Formulations:
Antithrombin III (human) 500 IU, 1000 IU; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Grifols Biologicals, Inc.
Indications for THROMBATE III:
Treatment of patients with hereditary antithrombin III deficiency (AT-III) in surgical or obstetrical procedures and thromboembolism.
Give by IV infusion over 10–20 minutes. Individualized. Dose (units required)= [desired (% of normal) – baseline (% of normal) AT-III level] X weight (kg)/1.4. Loading dose: increase AT-III to 120% of normal. Subsequent dose should be based on AT-III levels obtained 20 minutes post-infusion, every 12hrs, and before the next dose. Maintain AT-III levels at 80–120% of normal for 2–8 days.
Surgery. Hemorrhage. Acute thrombosis. Monitor AT-III levels during treatment. Contains human plasma; monitor for possible infection transmission. Pregnancy (Cat.B).
Potentiates anticoagulant effect of heparin; reduce heparin dose.
Thrombin inhibitor (α2-glycoprotein).
Dizziness, chest tightness, nausea, taste disturbances, chills, cramps, shortness of breath, chest pain, light-headedness, bowel fullness, hives, fever, hematoma formation.
Report all infections suspected to be transmitted by Thrombate III to (800) 520-2807.
Single-use vial—1 (w. diluent, needles)
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine